
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/845105/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 2023, 21, 1523-1532.e1.	4.4	31
2	Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease. Journal of Hepatology, 2022, 76, 283-293.	3.7	106
3	Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease. Journal of Hepatology, 2022, 76, 526-535.	3.7	80
4	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. JHEP Reports, 2022, 4, 100409.	4.9	20
5	The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet, The, 2022, 399, 61-116.	13.7	257
6	PSD3 downregulation confers protection against fatty liver disease. Nature Metabolism, 2022, 4, 60-75.	11.9	15
7	Why does obesity cause diabetes?. Cell Metabolism, 2022, 34, 11-20.	16.2	183
8	Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. Journal of Hepatology, 2022, 76, 1001-1012.	3.7	54
9	Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2008-e2020.	3.6	27
10	In vitro Effects of Bacterial Exposure on Secretion of Zonulin Family Peptides and Their Detection in Human Tissue Samples. Frontiers in Microbiology, 2022, 13, 848128.	3.5	5
11	LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover. Gut, 2021, 70, 180-193.	12.1	86
12	The PNPLA3-I148M Variant Confers an Antiatherogenic Lipid Profile in Insulin-resistant Patients. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e300-e315.	3.6	17
13	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. Journal of Hepatology, 2021, 74, 20-30.	3.7	77
14	Impact of short-term overfeeding of saturated or unsaturated fat or sugars on the gut microbiota in relation to liver fat in obese and overweight adults. Clinical Nutrition, 2021, 40, 207-216.	5.0	28
15	Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease. Gastroenterology, 2021, 160, 1634-1646.e7.	1.3	82
16	Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus. Advanced Science, 2021, 8, 2004168.	11.2	10
17	Dietary carbohydrates and fats in nonalcoholic fatty liver disease. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 770-786.	17.8	108
18	<i>NR1H4</i> rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. Liver International. 2021. 41. 2712-2719.	3.9	6

#	Article	IF	CITATIONS
19	Overfeeding Saturated Fat Increases LDL (Low-Density Lipoprotein) Aggregation Susceptibility While Overfeeding Unsaturated Fat Decreases Proteoglycan-Binding of Lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2823-2836.	2.4	12
20	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. Journal of Hepatology, 2021, 75, 770-785.	3.7	149
21	Assessment of Lifestyle Factors Helps to Identify Liver Fibrosis Due to Non-Alcoholic Fatty Liver Disease in Obesity. Nutrients, 2021, 13, 169.	4.1	9
22	Natural Course of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Patients With Human Immunodeficiency Virus With and Without Combination Antiretroviral Therapy–associated Lipodystrophy: A 16-Year Follow-up Study. Clinical Infectious Diseases, 2020, 70, 1708-1716.	5.8	6
23	Reply to Krahn and Sebastiani. Clinical Infectious Diseases, 2020, 71, 245-245.	5.8	Ο
24	Ceramides: A Cause of Insulin Resistance in Nonalcoholic Fatty Liver Disease in Both Murine Models and Humans. Hepatology, 2020, 71, 1499-1501.	7.3	17
25	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemporary Clinical Trials, 2020, 98, 106175.	1.8	71
26	Carbohydrate restriction reverses NAFLD by altering hepatic mitochondrial fluxes in humans. Journal of Hepatology, 2020, 73, S14.	3.7	0
27	Macrophage scavenger receptor 1 mediates lipid-induced inflammation in human obesity-related non-alcoholic fatty liver disease. Journal of Hepatology, 2020, 73, S20-S21.	3.7	Ο
28	The PNPLA3â€I148M variant increases polyunsaturated triglycerides in human adipose tissue. Liver International, 2020, 40, 2128-2138.	3.9	17
29	MARC1 variant rs2642438 increases hepatic phosphatidylcholines and decreases severity of non-alcoholic fatty liver disease in humans. Journal of Hepatology, 2020, 73, 725-726.	3.7	39
30	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology, 2020, 158, 1999-2014.e1.	1.3	1,840
31	Quantitative PCR provides a simple and accessible method for quantitative microbiota profiling. PLoS ONE, 2020, 15, e0227285.	2.5	207
32	OBEDIS Core Variables Project: European Expert Guidelines on a Minimal Core Set of Variables to Include in Randomized, Controlled Clinical Trials of Obesity Interventions. Obesity Facts, 2020, 13, 1-28.	3.4	15
33	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology, 2020, 73, 202-209.	3.7	2,171
34	Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 7347-7354.	7.1	137
35	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohortâ ⁻ †. Journal of Hepatology, 2020, 73, 505-515.	3.7	279
36	Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease. JCI Insight, 2020, 5, .	5.0	62

#	Article	IF	CITATIONS
37	Effects of Weighted Hula-Hooping Compared to Walking on Abdominal Fat, Trunk Muscularity, and Metabolic Parameters in Overweight Subjects: A Randomized Controlled Study. Obesity Facts, 2019, 12, 385-396.	3.4	7
38	Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids. JCI Insight, 2019, 4, .	5.0	93
39	Better glycaemic control and less hypoglycaemia with insulin glargine 300 <scp>U/mL</scp> vs glargine 100 <scp>U/mL</scp> : 1â€year patientâ€level metaâ€analysis of the <scp>EDITION</scp> clinical studies in people with type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 541-548.	4.4	69
40	Metabolomes of mitochondrial diseases and inclusion body myositis patients: treatment targets and biomarkers. EMBO Molecular Medicine, 2018, 10, .	6.9	54
41	Saturated Fat Is More Metabolically Harmful for the Human Liver Than Unsaturated Fat or Simple Sugars. Diabetes Care, 2018, 41, 1732-1739.	8.6	266
42	Diabetes, Liver Cancer, and Cirrhosis: What Next?. Hepatology, 2018, 68, 1220-1222.	7.3	6
43	Fat accumulates preferentially in the right rather than the left liver lobe in non-diabetic subjects. Digestive and Liver Disease, 2018, 50, 168-174.	0.9	7
44	Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD. Journal of Hepatology, 2017, 67, 128-136.	3.7	97
45	Serum Insulin Bioassay Reflects Insulin Sensitivity and Requirements in Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3814-3821.	3.6	3
46	Predictors of Liver Fat and Stiffness in Non-Alcoholic Fatty Liver Disease (NAFLD) – an 11-Year Prospective Study. Scientific Reports, 2017, 7, 14561.	3.3	18
47	Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study. Diabetologia, 2017, 60, 1873-1882.	6.3	85
48	Obesity/insulin resistance rather than liver fat increases coagulation factor activities and expression in humans. Thrombosis and Haemostasis, 2017, 117, 286-294.	3.4	18
49	Out of the frying pan: dietary saturated fat influences nonalcoholic fatty liver disease. Journal of Clinical Investigation, 2017, 127, 454-456.	8.2	21
50	Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD—A Systematic Review. International Journal of Molecular Sciences, 2016, 17, 633.	4.1	114
51	Continuous Grading of Early Fibrosis in NAFLD Using Label-Free Imaging: A Proof-of-Concept Study. PLoS ONE, 2016, 11, e0147804.	2.5	34
52	Phosphorylated IGFBP-1 as a non-invasive predictor of liver fat in NAFLD. Scientific Reports, 2016, 6, 24740.	3.3	21
53	WHY DOES NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) CONTRIBUTE TO CARDIOVASCULAR OUTCOMES?. Artery Research, 2016, 16, 46.	0.6	0
54	Diagnosis of non-alcoholic fatty liver disease (NAFLD). Diabetologia, 2016, 59, 1104-1111.	6.3	76

#	Article	IF	CITATIONS
55	The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans. Journal of Hepatology, 2016, 65, 1263-1265.	3.7	140
56	Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease. Nature Communications, 2016, 7, 8994.	12.8	103
57	Noninvasive Detection of Nonalcoholic Steatohepatitis UsingÂClinical Markers and Circulating Levels of Lipids andÂMetabolites. Clinical Gastroenterology and Hepatology, 2016, 14, 1463-1472.e6.	4.4	120
58	Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2016, 64, 1167-1175.	3.7	342
59	Novel hepatic microRNAs upregulated in human nonalcoholic fatty liver disease. Physiological Reports, 2016, 4, e12661.	1.7	41
60	Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes. Diabetes Technology and Therapeutics, 2016, 18, 252-257.	4.4	42
61	MicroRNA-192* impairs adipocyte triglyceride storage. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 342-351.	2.4	27
62	Effect of 3 Years of Treatment With Exenatide on Postprandial Glucagon Levels. Diabetes Care, 2016, 39, e42-e43.	8.6	9
63	Influence of Ethnicity on the Accuracy of Non-Invasive Scores Predicting Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2016, 11, e0160526.	2.5	26
64	Heterogeneity of nonâ€alcoholic fatty liver disease. Liver International, 2015, 35, 2498-2500.	3.9	15
65	Low Levels of Unmodified Insulin Glargine in Plasma of People With Type 2 Diabetes Requiring High Doses of Basal Insulin. Diabetes Care, 2015, 38, e96-e97.	8.6	2
66	Nutritional Modulation of Non-Alcoholic Fatty Liver Disease and Insulin Resistance. Nutrients, 2015, 7, 9127-9138.	4.1	117
67	Liver Fat Content and Hepatic Insulin Sensitivity in Overweight Patients With Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 607-616.	3.6	43
68	The influence of sample collection methodology and sample preprocessing on the blood metabolic profile. Bioanalysis, 2015, 7, 991-1006.	1.5	32
69	Ketone body production is differentially altered in steatosis and nonâ€elcoholic steatohepatitis in obese humans. Liver International, 2015, 35, 1853-1861.	3.9	62
70	Impact of nonâ€alcoholic fatty liver disease on liver volume in humans. Hepatology Research, 2015, 45, 210-219.	3.4	16
71	Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease. Diabetes and Vascular Disease Research, 2015, 12, 249-257.	2.0	13
72	Regulation of Angiopoietin-Like Proteins (ANGPTLs) 3 and 8 by Insulin. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1299-E1307.	3.6	72

#	Article	IF	CITATIONS
73	Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2. Journal of Hepatology, 2015, 62, 657-663.	3.7	104
74	Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease. Cell Cycle, 2014, 13, 1489-1494.	2.6	54
75	PNPLA3 mediates hepatocyte triacylglycerol remodeling. Journal of Lipid Research, 2014, 55, 739-746.	4.2	96
76	Altered miRNA processing disrupts brown/white adipocyte determination and associates with lipodystrophy. Journal of Clinical Investigation, 2014, 124, 3339-3351.	8.2	149
77	Circulating Triacylglycerol Signatures in Nonalcoholic Fatty Liver Disease Associated With the I148M Variant in PNPLA3 and With Obesity. Diabetes, 2014, 63, 312-322.	0.6	58
78	Less Nocturnal Hypoglycemia and Weight Gain with New Insulin Glargine 300 U/mL Compared with 100 U/mL: 1-Year Results in People with T2DM Using Basal Insulin with OADs (EDITION 2). Canadian Journal of Diabetes, 2014, 38, S5.	0.8	2
79	Sustained Glycemic Control and Less Hypoglycemia with New Insulin Glargine 300 U/mL Compared with 100 U/mL: 1-Year Results in People with T2DM Using Basal + Mealtime Insulin (EDITION 1). Canadian Journal of Diabetes, 2014, 38, S8-S9.	0.8	2
80	Effects of dietary interventions on liver volume in humans. Obesity, 2014, 22, 989-995.	3.0	34
81	Michaela Diamant, 11 April 1962–9 April 2014. Diabetologia, 2014, 57, 1271-1272.	6.3	1
82	New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2). Diabetes Care, 2014, 37, 3235-3243.	8.6	246
83	Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes and Endocrinology,the, 2014, 2, 901-910.	11.4	938
84	A population-based study on the prevalence of NASH using scores validated against liver histology. Journal of Hepatology, 2014, 60, 839-846.	3.7	107
85	Fatty liver score and 15-year incidence of type 2 diabetes. Hepatology International, 2013, 7, 610-621.	4.2	11
86	Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids. Diabetologia, 2013, 56, 2266-2274.	6.3	129
87	Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes. Diabetes Care, 2013, 36, 3875-3881.	8.6	124
88	Concentrations of Insulin Glargine and Its Metabolites During Long-Term Insulin Therapy in Type 2 Diabetic Patients and Comparison of Effects of Insulin Glargine, Its Metabolites, IGF-I, and Human Insulin on Insulin and IGF-I Receptor Signaling. Diabetes, 2013, 62, 2539-2544.	0.6	19
89	17β-Estradiol and Estradiol Fatty Acyl Esters and Estrogen-Converting Enzyme Expression in Adipose Tissue in Obese Men and Women. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4923-4931.	3.6	34
90	Is There Evidence to Support Use of Premixed or Prandial Insulin Regimens in Insulin-Naive or Previously Insulin-Treated Type 2 Diabetic Patients?. Diabetes Care, 2013, 36, S205-S211.	8.6	8

#	Article	IF	CITATIONS
91	PNPLA3 is regulated by glucose in human hepatocytes, and its I148M mutant slows down triglyceride hydrolysis. American Journal of Physiology - Endocrinology and Metabolism, 2012, 302, E1063-E1069.	3.5	76
92	Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans. American Journal of Clinical Nutrition, 2012, 96, 727-734.	4.7	171
93	Should we treat infection or inflammation to prevent T2DM?. Nature Reviews Endocrinology, 2012, 8, 323-325.	9.6	25
94	Isoform-specific alanine aminotransferase measurement can distinguish hepatic from extrahepatic injury in humans. International Journal of Molecular Medicine, 2012, 30, 1241-1249.	4.0	22
95	Metabolomic analysis of polar metabolites in lipoprotein fractions identifies lipoprotein-specific metabolic profiles and their association with insulin resistance. Molecular BioSystems, 2012, 8, 2559.	2.9	12
96	Genetic variation in <i>PNPLA3</i> but not <i>APOC3</i> influences liver fat in nonâ€elcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 951-956.	2.8	49
97	Waist Circumference Adjusted for Body Mass Index and Intra-Abdominal Fat Mass. PLoS ONE, 2012, 7, e32213.	2.5	22
98	Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. Journal of Hepatology, 2011, 54, 153-159.	3.7	123
99	Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease. Liver International, 2011, 31, 176-183.	3.9	95
100	FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. Lancet Neurology, The, 2011, 10, 806-818.	10.2	352
101	Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss–induced decrease in liver fat in humans. American Journal of Clinical Nutrition, 2011, 94, 104-111.	4.7	131
102	Comparison of Dorsocervical With Abdominal Subcutaneous Adipose Tissue in Patients With and Without Antiretroviral Therapy–Associated Lipodystrophy. Diabetes, 2011, 60, 1894-1900.	0.6	16
103	Effects of Exenatide on Measures of β-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes. Diabetes Care, 2011, 34, 2041-2047.	8.6	221
104	Association of Lipidome Remodeling in the Adipocyte Membrane with Acquired Obesity in Humans. PLoS Biology, 2011, 9, e1000623.	5.6	213
105	Nutritional modulation of nonalcoholic fatty liver disease and insulin resistance: human data. Current Opinion in Clinical Nutrition and Metabolic Care, 2010, 13, 709-714.	2.5	63
106	Skeletal muscle mitochondrial DNA content and aerobic metabolism in patients with antiretroviral therapy-associated lipoatrophy. Journal of Antimicrobial Chemotherapy, 2010, 65, 1497-1504.	3.0	2
107	Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition. Diabetes Care, 2010, 33, 1734-1737.	8.6	139
108	Allele-specific regulation of MTTP expression influences the risk of ischemic heart disease. Journal of Lipid Research, 2010, 51, 103-111.	4.2	18

#	Article	IF	CITATIONS
109	Use of Genome-Wide Expression Data to Mine the "Gray Zone―of GWA Studies Leads to Novel Candidate Obesity Genes. PLoS Genetics, 2010, 6, e1000976.	3.5	62
110	Nonalcoholic Fatty Liver Disease: Detection of Elevated Nicotinamide Adenine Dinucleotide Phosphate with in Vivo 3.0-T ³¹ P MR Spectroscopy with Proton Decoupling. Radiology, 2010, 256, 466-473.	7.3	48
111	Liver Fat in the Pathogenesis of Insulin Resistance and Type 2 Diabetes. Digestive Diseases, 2010, 28, 203-209.	1.9	98
112	From the metabolic syndrome to NAFLD or vice versa?. Digestive and Liver Disease, 2010, 42, 320-330.	0.9	406
113	Splanchnic Balance of Free Fatty Acids, Endocannabinoids, and Lipids in Subjects With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2010, 139, 1961-1971.e1.	1.3	61
114	One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis, 2010, 212, 223-229.	0.8	118
115	Hepatic Stearoyl-CoA Desaturase (SCD)-1 Activity and Diacylglycerol but Not Ceramide Concentrations Are Increased in the Nonalcoholic Human Fatty Liver. Diabetes, 2009, 58, 203-208.	0.6	210
116	Genetic variation in the ADIPOR2 gene is associated with liver fat content and its surrogate markers in three independent cohorts. European Journal of Endocrinology, 2009, 160, 593-602.	3.7	76
117	Congruence between NOTCH3 mutations and GOM in 131 CADASIL patients. Brain, 2009, 132, 933-939.	7.6	166
118	Liver fat and lipid oxidation in humans. Liver International, 2009, 29, 1439-1446.	3.9	89
119	One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients. Diabetes Care, 2009, 32, 762-768.	8.6	354
120	Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: A study in monozygotic and dizygotic twins. Journal of Hepatology, 2009, 50, 1035-1042.	3.7	124
121	Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors. Gastroenterology, 2009, 137, 865-872.	1.3	646
122	Thiazolidinediones and the liver in humans. Current Opinion in Lipidology, 2009, 20, 477-483.	2.7	49
123	Increased Liver Fat, Impaired Insulin Clearance, and Hepatic and Adipose Tissue Insulin Resistance in Type 2 Diabetes. Gastroenterology, 2008, 135, 122-130.	1.3	294
124	Long-Term Effects of Fenofibrate on Carotid Intima-Media Thickness and Augmentation Index in Subjects With Type 2 Diabetes Mellitus. Journal of the American College of Cardiology, 2008, 52, 2190-2197.	2.8	66
125	Fatty Liver. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 27-38.	2.4	717
126	Liver Fat Is Increased in Type 2 Diabetic Patients and Underestimated by Serum Alanine Aminotransferase Compared With Equally Obese Nondiabetic Subjects. Diabetes Care, 2008, 31, 165-169.	8.6	200

#	Article	IF	CITATIONS
127	Global Transcript Profiles of Fat in Monozygotic Twins Discordant for BMI: Pathways behind Acquired Obesity. PLoS Medicine, 2008, 5, e51.	8.4	265
128	Rosiglitazone Reduces Liver Fat and Insulin Requirements and Improves Hepatic Insulin Sensitivity and Glycemic Control in Patients with Type 2 Diabetes Requiring High Insulin Doses. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 118-124.	3.6	51
129	Insulin-Like Growth Factor Binding Protein 1 as a Novel Specific Marker of Hepatic Insulin Sensitivity. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4867-4872.	3.6	64
130	Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. Aids, 2008, 22, 227-236.	2.2	74
131	Postprandial Lipemia Associates with Liver Fat Content. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3052-3059.	3.6	70
132	Effects of Chronic Rosiglitazone Therapy on Gene Expression in Human Adipose Tissuein Vivoin Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 720-724.	3.6	66
133	Initiate Insulin by Aggressive Titration and Education (INITIATE): A randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care, 2007, 30, 1364-1369.	8.6	135
134	Genes Involved in Fatty Acid Partitioning and Binding, Lipolysis, Monocyte/Macrophage Recruitment, and Inflammation Are Overexpressed in the Human Fatty Liver of Insulin-Resistant Subjects. Diabetes, 2007, 56, 2759-2765.	0.6	306
135	Effect of liver fat on insulin clearance. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E1709-E1715.	3.5	174
136	Negative Binomial Meta-Regression Analysis of Combined Glycosylated Hemoglobin and Hypoglycemia Outcomes Across Eleven Phase III and IV Studies of Insulin Glargine Compared with Neutral Protamine Hagedorn Insulin in Type 1 and Type 2 Diabetes Mellitus. Clinical Therapeutics, 2007, 29, 1607-1619.	2.5	154
137	Liver Fat in the Metabolic Syndrome. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3490-3497.	3.6	386
138	Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity. Clinical Endocrinology, 2007, 66, 440-446.	2.4	149
139	Adipose Tissue Inflammation and Increased Ceramide Content Characterize Subjects With High Liver Fat Content Independent of Obesity. Diabetes, 2007, 56, 1960-1968.	0.6	279
140	Acquired Obesity Is Associated with Changes in the Serum Lipidomic Profile Independent of Genetic Effects – A Monozygotic Twin Study. PLoS ONE, 2007, 2, e218.	2.5	356
141	Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial. Antiviral Therapy, 2007, 12, 97-105.	1.0	47
142	Insulin Resistance, Arterial Stiffness and Wave Reflection. , 2006, 44, 252-260.		45
143	Acquired Obesity Increases CD68 and Tumor Necrosis Factor-α and Decreases Adiponectin Gene Expression in Adipose Tissue: A Study in Monozygotic Twins. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2776-2781.	3.6	65
144	Fatty acid metabolism in adipose tissue, muscle and liver in health and disease. Essays in Biochemistry, 2006, 42, 89-103.	4.7	219

#	Article	IF	CITATIONS
145	Glycodelin responses to hyperinsulinaemic clamp vary according to basal serum glycodelin concentration. Clinical Endocrinology, 2005, 62, 611-615.	2.4	3
146	The Contribution of Visceral Adipose Tissue to Splanchnic Cortisol Production in Healthy Humans. Diabetes, 2005, 54, 1364-1370.	0.6	93
147	The PROactive study: some answers, many questions. Lancet, The, 2005, 366, 1241-1242.	13.7	132
148	Comparison of Basal Insulin Added to Oral Agents Versus Twice-Daily Premixed Insulin as Initial Insulin Therapy for Type 2 Diabetes. Diabetes Care, 2005, 28, 254-259.	8.6	405
149	Dietary Fat Content Modifies Liver Fat in Overweight Nondiabetic Subjects. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2804-2809.	3.6	325
150	Fat in the liver and insulin resistance. Annals of Medicine, 2005, 37, 347-356.	3.8	235
151	Arterial Stiffness in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy. Antiviral Therapy, 2005, 10, 925-935.	1.0	37
152	Glargine and Regular Human Insulin Similarly Acutely Enhance Endothelium-Dependent Vasodilatation in Normal Subjects. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 320-324.	2.4	17
153	3.5 Years of Insulin Therapy With Insulin Glargine Improves In Vivo Endothelial Function in Type 2 Diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 325-330.	2.4	67
154	Overexpression of 11β-Hydroxysteroid Dehydrogenase-1 in Adipose Tissue Is Associated with Acquired Obesity and Features of Insulin Resistance: Studies in Young Adult Monozygotic Twins. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4414-4421.	3.6	207
155	Thiazolidinediones. New England Journal of Medicine, 2004, 351, 1106-1118.	27.0	1,892
156	Effects of Rosiglitazone and Metformin on Liver Fat Content, Hepatic Insulin Resistance, Insulin Clearance, and Gene Expression in Adipose Tissue in Patients With Type 2 Diabetes. Diabetes, 2004, 53, 2169-2176.	0.6	478
157	Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women. American Journal of Clinical Nutrition, 2004, 79, 22-30.	4.7	80
158	Growth Patterns in Young Adult Monozygotic Twin Pairs Discordant and Concordant for Obesity. Twin Research and Human Genetics, 2004, 7, 421-429.	1.0	1
159	Nonglycemic effects of insulin. Clinical Cornerstone, 2003, 5, S6-S12.	0.7	14
160	Insulin―and Exercise‣timulated Skeletal Muscle Blood Flow and Glucose Uptake in Obese Men. Obesity, 2003, 11, 257-265.	4.0	35
161	Insulin resistance and endothelial dysfunction. Best Practice and Research in Clinical Endocrinology and Metabolism, 2003, 17, 411-430.	4.7	58
162	Lowering of LDL Cholesterol Rather Than Moderate Weight Loss Improves Endothelium-Dependent Vasodilatation in Obese Women With Previous Gestational Diabetes. Diabetes Care, 2003, 26, 1667-1672.	8.6	68

#	Article	IF	CITATIONS
163	Effects of Identical Weight Loss on Body Composition and Features of Insulin Resistance in Obese Women With High and Low Liver Fat Content. Diabetes, 2003, 52, 701-707.	0.6	249
164	Regulation of Plasma PAI-1 Concentrations in HAART-Associated Lipodystrophy During Rosiglitazone Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 688-694.	2.4	72
165	Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. Aids, 2003, 17, 1753-1762.	2.2	103
166	Circulating Concentration of Adiponectin and Its Expression in Subcutaneous Adipose Tissue in Patients with Highly Active Antiretroviral Therapy-Associated Lipodystrophy. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1907-1910.	3.6	91
167	Body Fat Distribution and Cortisol Metabolism in Healthy Men: Enhanced 5β-Reductase and Lower Cortisol/Cortisone Metabolite Ratios in Men with Fatty Liver. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4924-4931.	3.6	163
168	Differential Effects of Oral and Transdermal Estradiol Treatment on Circulating Estradiol Fatty Acid Ester Concentrations in Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 588-593.	3.6	18
169	Rosiglitazone in the Treatment of Haart-Associated Lipodystrophy – a Randomized Double-Blind Placebo-Controlled Study. Antiviral Therapy, 2003, 8, 199-207.	1.0	164
170	Insulin-Induced Decreases in Aortic Wave Reflection and Central Systolic Pressure Are Impaired in Type 2 Diabetes. Diabetes Care, 2002, 25, 2314-2319.	8.6	51
171	Impaired Responsiveness to NO in Newly Diagnosed Patients With Rheumatoid Arthritis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1637-1641.	2.4	198
172	Arterial Stiffness and Insulin Resistance. Seminars in Vascular Medicine, 2002, 2, 157-164.	2.1	16
173	Inhibition of Platelet-Collagen Interaction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 167-172.	2.4	128
174	Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. Aids, 2002, 16, 2183-2193.	2.2	162
175	Fat Accumulation in the Liver Is Associated with Defects in Insulin Suppression of Glucose Production and Serum Free Fatty Acids Independent of Obesity in Normal Men. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3023-3028.	3.6	908
176	Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus. Diabetes/Metabolism Research and Reviews, 2002, 18, S77-S81.	4.0	36
177	Endothelial dysfunction in human diabetes. Current Diabetes Reports, 2002, 2, 26-36.	4.2	34
178	Liverâ€Fat Accumulation and Insulin Resistance in Obese Women with Previous Gestational Diabetes. Obesity, 2002, 10, 859-867.	4.0	137
179	Ectopic fat accumulation: an important cause of insulin resistance in humans. Journal of the Royal Society of Medicine, 2002, 95 Suppl 42, 39-45.	2.0	25
180	Multiple risk factor intervention in type 2 diabetes: an opportunity not to be missed. Diabetes, Obesity and Metabolism, 2001, 3, 1-8.	4.4	9

#	Article	IF	CITATIONS
181	Resistance to Exercise-Induced Increase in Glucose Uptake During Hyperinsulinemia in Insulin-Resistant Skeletal Muscle of Patients With Type 1 Diabetes. Diabetes, 2001, 50, 1371-1377.	0.6	38
182	Evidence for Spatial Heterogeneity in Insulin- and Exercise-Induced Increases in Glucose Uptake: Studies in Normal Subjects and Patients with Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5525-5533.	3.6	13
183	Resistance to Acute Insulin Induced Decreases in Large Artery Stiffness Accompanies the Insulin Resistance Syndrome. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5262-5268.	3.6	54
184	Regulation of hexokinase II expression in human skeletal muscle in vivo. Metabolism: Clinical and Experimental, 2000, 49, 814-818.	3.4	35
185	Management of Type 2 Diabetes Mellitus and Cardiovascular Risk. Drugs, 2000, 60, 975-983.	10.9	41
186	Independent Influence of Age on Basal Insulin Secretion in Nondiabetic Humans. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 863-868.	3.6	199
187	Metformin Prevents Weight Gain by Reducing Dietary Intake During Insulin Therapy in Patients with Type 2 Diabetes Mellitus. Drugs, 1999, 58, 53-54.	10.9	35
188	Glutamine: Fructose-6-phosphate amidotransferase activity and gene expression are regulated in a tissue-specific fashion in pregnant rats. Life Sciences, 1999, 65, 215-223.	4.3	11
189	Intense physical training decreases circulating antioxidants and endothelium-dependent vasodilatation in vivo. Atherosclerosis, 1999, 145, 341-349.	0.8	159
190	Autoantibodies against oxidized LDL and endothelium-dependent vasodilation in insulin-dependent diabetes mellitus. Atherosclerosis, 1999, 147, 115-122.	0.8	19
191	Free Fatty Acid Kinetics and Oxidation in Congestive Heart Failure. American Journal of Cardiology, 1998, 81, 45-50.	1.6	106
192	Toxicity of hyperglycaemia in Type 2 diabetes. Diabetes/metabolism Reviews, 1998, 14, S45-S50.	0.3	11
193	Insulin and glucosamine infusions increase O-linked N-acetyl-glucosamine in skeletal muscle proteins in vivo. Metabolism: Clinical and Experimental, 1998, 47, 449-455.	3.4	103
194	MODY genes and mutations in hepatocyte nuclear factors. Lancet, The, 1997, 349, 516-517.	13.7	18
195	Estimation of blood flow heterogeneity distribution in human skeletal muscle from positron emission tomography data. Annals of Biomedical Engineering, 1997, 25, 906-910.	2.5	29
196	The Effect of Insulin and FFA on Myocardial Glucose Uptake. Journal of Molecular and Cellular Cardiology, 1995, 27, 1359-1367.	1.9	60
197	Insulin increases the release of endothelin in endothelial cell cultures in vitro but not in vivo. Metabolism: Clinical and Experimental, 1994, 43, 878-882.	3.4	45
198	Pathogenesis of non-insulin-dependent diabetes mellitus. Lancet, The, 1994, 343, 91-95.	13.7	185

#	Article	IF	CITATIONS
199	Comparison of Insulin Regimens in Patients with Non-Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine, 1992, 327, 1426-1433.	27.0	330
200	Glucose Toxicity*. Endocrine Reviews, 1992, 13, 415-431.	20.1	276
201	No Evidence for Short-Term Regulation of Plasminogen Activator Inhibitor Activity by Insulin in Man. Thrombosis and Haemostasis, 1992, 67, 117-120.	3.4	42
202	Effect of Free Fatty Acids on Glucose Uptake and Nonoxidative Glycolysis across Human Forearm Tissues in the Basal State and during Insulin Stimulation*. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 1268-1277.	3.6	99
203	Evidence for a Primary Roie of Insulin Resistance in the Pathogenesis of Type 2 Diabetes. Annals of Medicine, 1990, 22, 197-200.	3.8	13
204	Changes in Muscle Glucose Metabolism in Type 1 Diabetes. Annals of Medicine, 1990, 22, 201-205.	3.8	11
205	Regulation of plasma lactate concentration in resting human subjects. Metabolism: Clinical and Experimental, 1990, 39, 859-864.	3.4	47
206	Dose-Response Characteristics for Suppression of Low Molecular Weight Plasma Insulin-Like Growth Factor-Binding Protein by Insulin*. Journal of Clinical Endocrinology and Metabolism, 1989, 68, 135-140.	3.6	205
207	Prolonged Exercise Increases Serum Insulin-Like Growth Factor-Binding Protein Concentrations*. Journal of Clinical Endocrinology and Metabolism, 1989, 68, 141-144.	3.6	105
208	Severity, Duration, and Mechanisms of Insulin Resistance during Acute Infections*. Journal of Clinical Endocrinology and Metabolism, 1989, 69, 317-323.	3.6	116
209	Clinical benefits and mechanisms of a sustained response to intermittent insulin therapy in type 2 diabetic patients with secondary drug failure. American Journal of Medicine, 1988, 84, 185-192.	1.5	53
210	Insulin Regulates the Serum Levels of Low Molecular Weight Insulin-Like Growth Factor-Binding Protein*. Journal of Clinical Endocrinology and Metabolism, 1988, 66, 266-272.	3.6	528
211	Impaired Glucose Tolerance as a Disorder of Insulin Action. New England Journal of Medicine, 1988, 318, 1217-1225.	27.0	558
212	Natural Course of Insulin Resistance in Type I Diabetes. New England Journal of Medicine, 1986, 315, 224-230.	27.0	323
213	Smoking and insulin sensitivity in type I diabetic patients. Metabolism: Clinical and Experimental, 1986, 35, 874-877.	3.4	30
214	Insulin resistance is a prominent feature of patients with pancreatogenic diabetes. Metabolism: Clinical and Experimental, 1986, 35, 718-727.	3.4	46
215	The Effect of Exogenous Hyperinsulinemia on Proinsulih Secretion in Normal Man, Obese Subjects, and Patients with Insulinoma*. Journal of Clinical Endocrinology and Metabolism, 1986, 63, 1117-1120.	3.6	44
216	No association between retinopathy and insulin resistance in type 1 diabetes. European Journal of Endocrinology, 1986, 111, 522-527.	3.7	3

#	Article	IF	CITATIONS
217	Insulin binding and action in adipocytes in vitro in relation to insulin action in vivo in young and middle-aged subjects. European Journal of Endocrinology, 1986, 113, 88-92.	3.7	17
218	Relationship between oral glucose tolerance and insulin sensitivity in healthy man and type 1 diabetic patients. European Journal of Endocrinology, 1986, 112, 355-360.	3.7	6
219	Ethanol Decreases Clucose Utilization In Healthy Man*. Journal of Clinical Endocrinology and Metabolism, 1985, 61, 941-945.	3.6	123
220	Site of Insulin Resistance in Type 1 Diabetes: Insulin-Mediated Glucose Disposal <i>in Vivo</i> in Relation to Insulin Binding and Action in Adipocytes <i>in Vitro</i> *. Journal of Clinical Endocrinology and Metabolism, 1984, 59, 1183-1192.	3.6	51
221	The occurrence of relaxin in hyperstimulated human preovulatory follicles collected in an in vitro fertilization program. Journal of in Vitro Fertilization and Embryo Transfer: IVF, 1984, 1, 180-182.	0.8	11
222	Insulin Sensitivity in Newly Diagnosed Type 1 Diabetics after Ketoacidosis and after Three Months of Insulin Therapy*. Journal of Clinical Endocrinology and Metabolism, 1984, 59, 371-378.	3.6	88
223	Continuous Subcutaneous Insulin Infusion Therapy Decreases Insulin Resistance in Type 1 Diabetes*. Journal of Clinical Endocrinology and Metabolism, 1984, 58, 659-666.	3.6	123
224	Sex and insulin sensitivity. Metabolism: Clinical and Experimental, 1984, 33, 1011-1015.	3.4	146
225	Immunohistochemical demonstration of relaxin in gynecologic tumors. Cancer, 1983, 52, 2077-2080.	4.1	9
226	Solubilization and preliminary characterization of the human ileal vitamin B ₁₂ -intrinsic factor receptor. Scandinavian Journal of Clinical and Laboratory Investigation, 1979, 39, 461-467.	1.2	6